Allied Academies Organizes Pharma Summit 2019 conference along with 300+ Conferences across the USA, Europe & Asia every year with support from 1000 more scientific societies and Publishes 400+ Open access journals which contain over 30000 eminent personalities as editorial board members.
We invite you to join us at the Pharma Summit 2019 where you will be sure to have a meaningful experience with scholars from around the world. All members of the Pharma Summit 2019 organizing committee look forward to meeting you in Valencia, Spain.
Key-dates | Abstract Submission | Registration Guidelines
On behalf of the Allied Academies conferences, it is my pleasure to
invite all of the great scientists, academicians, young researchers, Business
delegates and students from all over the world to attend the 2nd Global Pharma Summit from July 18-19, 2019
at Valencia, Spain.
Allied Academies cordially welcomes all the
attendees, speakers, sponsor’s and other research expertise from all over the
world to the “2nd Global Pharma Summit
( Pharma Summit 2019)
which is going to be held during july18-19, 2019 in Valencia, Spain. We are
very much honoured to invite you all to exchange and share your views and
experience in our pharma conference: “Exploring the
Pharma Research & Inventing a Formula for Drug Development".
Pharma Summit 2019 has over 17sessions designed to offer a comprehensive outlook that addresses current issues in Pharma Research and in Healthcare System. Speakers are allocated specific slots corresponding to their session.
The abstract/s can be submitted online under Submit Abstract in Homepage or through e-mail at firstname.lastname@example.org
The completed registrations/ is/are to be received per attendee and the corresponding payment in Dollar by the given deadlines. Please note that the registrations are available on-site too. But, we strongly emphasize to register in advance rather spot registration.
Each year, the Allied Academies offers the following merit-based award to support select trainees with high-achieving annual meeting abstracts who are selected to present their work at the Allied Academies annual meeting. Trainees include those who fall within one of the following categories: Graduates, Post Graduates and Research Scholars.
Abstract submission site opens
Abstract submission deadline
3, 2019, 11: 59 p.m. Pacific time
Pharmaceutical formulation is the process of combining various chemicalsubstances with the active drug to form a final medicinal product, which iscalled a drug mixture or drug formulation.A drug formulation can be given to the patient in various forms like solid,semisolid or liquid. The type of the formulation given depends upon thepatient’s age, sex, and health condition and is specific for particular routes of administration.
An analytical technique is amethod that is used to determine the concentration of a chemical compound orchemical element. There are a wide variety of techniques used for analysis,from simple weighing (gravimetric analysis) to titrations (titrimetric) to veryadvanced techniques using highly specialized instrumentation. From the stagesof drug development to marketing and post marketing, analytical techniques playa great role, be it understanding the physical and chemical stability of the drug, impact on theselection and design of the dosage form, assessing thestability of the drug molecules,quantitation of the impurities and identification of those impurities which areabove the established threshold essential to evaluate the toxicity profiles ofthese impurities to distinguish these from that of the active pharmaceutical ingredient(API).
Track 1: Pharmaceutical Formulations:
Pharmaceutical formulation inpharmaceutics is the process in which various chemicalsubstances including the vigorous drug are joined to produce a final medicinalproduct. Formulation studies involve developing a preparation ofthe drug which is both stable and acceptable to the patient. Fororally taken drugs, this usually contains combining the drug into a tabletor a capsule. Formulations confirm that the drug is compatible withthese other substances. In the pharmaceutical drug formulations, the differentphysical, chemical, and mechanical properties of a drug are considered soas to know what other ingredients should be used in the preparation. Thevarious factors like polymorphism, particle size, pH, and solubility areall considered while formulating the drug, also considering the appearance ofthe tablet.
Track 2: Pre-Formulation Studies:
The drug discovery starts with Pre-formulation Studies which isinitiated by Disease Identification then carried onto suitable drugidentification then after StabilityAnalysis of Drug, Behavioural Analysis, Dissolution, HighPerformance Liquid Chromatography or Nuclear Magnetic Resonance (NMR) as perthe ICH guidelines.
The global market for Pre-formulationstudies that is for the drug discovery technologiesreached nearly $39.5 billion and $46.5 billion in 2013 and 2014, respectively.This market is expected to grow at a compound annual growth rate (CAGR) of11.3% to nearly $79.5 billion for the period 2014-2019
· Crystallinty and Polymorphism
· Fine Particle Characterization
· Powder Flow Properties
· Ionization constant-PKa
· PH solubility profile
· Common ion effect-Ksp
· Thermal effects
Track 3: Drug Design:
It is the process of producing or invention of novel and/ or new medicalproduct, the design of this new product completely based on the knowledge ofbiological target. Moreover, this process sometimes known as or called rational drug design. Ligand-baseddrug design- In this branch or type of pharmaceutical formulation the design of the drug will bemade or built depends on the knowledge of what binds to it. Structure-based-while this type drug design will depend on the information related with thethree dimensional structure of the biological target these information will begotten by using methods like X-ray or NMR.
Track 4: FormulationR&D:
The drug subjectedto drug development undergoes number of trials and are screened atdifferent stages to produce a final potent drug intended for thetreatment of various diseases. During this process various properties arechecked to see whether the drug is non-toxic to living system and istherapeutic or not. Using suitable excipients and technologicalpreparations the active substances are formulated into final dosage form.The last product is the Actual composition of preparation, manufacturingspecification. Drug formulation can have a substantial impact on almost everyquality characteristic of an API including potency, bioavailability, solubility, dosage, route of administration andstability. In immune offersparenteral drug formulation R&D services for primary stageand preclinical candidates with a special prominence in nanoparticlebased drug delivery technology.
Track 5: Clinical Research Vs Clinical Trails:
In clinical research the scientists do experiments with a health intervention in anattempt to find enough evidence for a process which would be useful as amedical treatment. In the case of pharmaceutical study, the phases start withdrug design and drug discovery then proceed on to animal testing. If this issuccessful, they begin the clinical phase of development by testing for safetyin a few human subjects and expand to test in many study participants todetermine if the treatment is effective.
Clinical trials involving new drugs are commonly classified into four phases.Individual trials may encompass more than one phase. A common example of thisis combined phase I/II or phase II/III trials. Therefore, it may be easier tothink of early phase studies and late phase studies. The drug-developmentprocess will normally proceed through all four phases over many years. If thedrug successfully passes through Phases I, II, and III, it will usually beapproved by the national regulatory authority for use in the generalpopulation. Phase IV are 'post-approval' studies.
Track 6: Bioavailability and Bioequivalence Studies:
Bioavailability isa subcategory of absorption and isthe fraction of an administered dose of unchanged drug that reaches thesystemic circulation, one of the principal pharmacokinetic properties of drugs.when a medication is administered intravenously, its bioavailability is 100%.when a medication is administered via other routes (such as orally), itsbioavailability decreases (due to incomplete absorption and first-passmetabolism) or may vary from patient to patient. Bioavailability is one of theessential tools in pharmacokinetics, as bioavailability must be considered whencalculating dosages for non-intravenous routes of administration.
In determining bioequivalence, for example,between two products such as a commercially available Brand product and apotential to-be-marketed Generic product, pharmacokinetic studies are conductedwhereby each of the preparations are administered in a cross-over study tovolunteer subjects, generally healthy individuals but occasionally in patients.Serum/plasma samples are obtained at regular intervals and assayed for parentdrug (or occasionally metabolite) concentration. Occasionally, bloodconcentration levels are either feasible or possible to compare the twoproducts (e.g. inhaled corticosteroids), then pharmacodynamic endpoints ratherthan pharmacokinetic endpoints are used for comparison. For a pharmacokineticcomparison, the plasma concentration data are used to assess keypharmacokinetic parameters such as area under the curve (AUC), peakconcentration (Cmax), time to peak concentration (Tmax), and absorption lagtime (tlag). Testing should be conducted at several different doses, especiallywhen the drug displays non-linear pharmacokinetics.
Track 7: Pharmaceutical Freeze DryingTechnology:
Pharmaceutical freeze Technologyis the removal of ice or other frozen solvents from a material through theprocess of sublimation and the removal of bound water molecules through theprocess of desorption. Lyophilisation and freeze drying are termsthat are used interchangeably depending on the industry and location where thedrying is taking place. Controlled freeze drying keeps the product temperaturelow enough during the process to avoid changes in the dried product appearanceand characteristics. It is an first-rate method for preserving a wide diversityof heat-sensitive materials such as proteins, microbes, pharmaceuticals,tissues & Plasma.
Track 8: Nano Medicine & NanoTechnology:
Nanomedicine is the medicalapplication of nanotechnology. Nanomedicine ranges from the medicalapplications of nanomaterials and biological devices, to nanoelectronicbiosensors, and even possible future applications of molecular nanotechnologysuch as biological machines. Nanotechnology has provided the possibility ofdelivering drugs to specific cells using nanoparticles.The overall drugconsumption and side-effects may be lowered significantly by depositing theactive agent in the morbid region only and in no higher dose than needed.Targeted drug delivery is intended to reduce the side effects of drugs withconcomitant decreases in consumption and treatment expenses. Drug deliveryfocuses on maximizing bioavailability both atspecific places in the body and over a period of time. This can potentially beachieved by molecular targeting by Nano engineered devices. A benefit of usingnanoscale for medical technologies is that smaller devices are less invasiveand can possibly be implanted inside the body, plus biochemical reaction timesare much shorter. These devices are faster and more sensitive than typical drugdelivery. The efficacy of drug delivery through nanomedicine is largely basedupon efficient encapsulation of the drugs, successful delivery of drug to thetargeted region of the body, successful release of the drug.
Track 9: Analytical Method Development and Validation:
Analyticalmethod development is the process of choosing an accurateassay procedure to determine the composition of a formulation. It is theprocess of proving that an analytical method is acceptable for use inlaboratory to measure the concentration of subsequent samples Analyticalmethods should be recycled within GMP and GLP environments and must bedeveloped using the protocols and acceptance conditions set out in the ICHguidelines. Analytical method development and validation stand the continuousand inter-dependent task associated with the research anddevelopment, quality control and qualityassurance departments. Analytical procedures play a critical role inequivalence and risk assessment, management. It supports in formation ofproduct-specific acceptance criteria and stability of results. Validationshould establish that the analytical procedure is suitable for itsintended purpose. Design of experiment is a powerful tool for the methodcharacterization and validation.
Track 10: Advances in Chromatography and Mass Spectrometry:
Chromatography and mass Spectrometry qualitative analysisis employed for analysis of organic compounds. Electro spray ionization(ESI) could be a technique employed in mass spectroscopic analysis. Ascompare to chromatography and mass spectrometry, HPLC is more flexibleinformative and trusted by the industry people. Recent advances in samplepreparation techniques to beat difficulties encountered throughout measuring oflittle molecules from bio fluids mistreatment LC-MS. For Measuring, observationand protective your important Investments analytical chemistry instruments areused. Lipidomics, as a novel branch of metabolomics, which is aimed at comprehensive analysis of lipidsand their biological roles with respect to health and diseases, has attractedincreased attention from biological and analytical scientists. As a result ofthe complexity and diversity of lipids, accurate identification and efficientseparation are required for lipidomics analysis. Mass spectrometry (MS) and chromatography have been extensively developed in the past fewdecades and hold a distinguished position in qualification and separation science.They are powerful and indispensable tools for lipidomics.
· Role ofSpectroscopy as Separation Technique
· Innovationsin Mass Spectrometry techniques
· MassSpectrometry in Proteome Research
· Ion-MobilitySpectrometry-Mass Spectrometry (IMS-MS)
· LiquidChromatography Mass Spectrometry (LC-MS)
Track 11: Novel Approaches to Analyticaland Bio Analytical Methods:
Analytical chemistry isthat the study of the separation, identification, quality control andquality assurance of the chemical parts of natural and artificial materials.The maintenance of a desired level of quality in an exceptionally package orproduct, particularly by resources that of attention to every one stage of themethod of delivery or production. Bio analytical Chemistry could be asub-division of Analytical Chemistry that refuges the measuring of medicine,Ion sensors, Proteins and DNA Sequences in unnatural samples orconcentrations. Accurate quantification of the drug samples is extremely veryimportant for several scientific endeavors which cannot delay the result.Therefore the Bio analytical Techniques arein the main focused to bring the correct results of the drug sample to supplyan ideal result.
· DNA sequencing
· Ion sensors
· Method developmentand validation reports
· Detect fake drugsquickly
Track 12: Latest Drug Development instruments:
Ultra Fast MW Confirmation LC/MS System forSynthetic Compounds: Once a target compound is synthesized, it needs to beconfirmed as quickly as possible for downstream processes. An Ultra Fast MWConfirmation system consisting of Nexera UHPLC and an LCMS-2020 massspectrometer is a powerful choice for such analysis. LCMS-2020 captures all thenarrow peaks separated by Prominence UFLC in shorter run times. LCMS softwarealso supports easier operation and integrated workflows.
Preparative Isolation LC System with MS forChemical Synthesis: Highpurity and high efficiency are important in preparative isolation process,particularly for such next steps as efficacy and pharmacokinetic studies.Shimadzu LC modular systems are flexible and allow configurations required forpreparative scale chromatography. PsiPortTM software and the LCMS-2020 massspectrometer ensure qualitative and quantitative analyses of target fractions.A 'one click' approach to sample analysis allows to use pre-configured methodsand customized reporting templates.
Track 13: Industrial Pharmacy & Physical Pharmacy:
By definition IndustrialPharmacy is a discipline which includes manufacturing, development, marketingand distribution of drug products including quality assurance of theseactivities. This broad research area relates to different functions inpharmaceutical industry and having contact areas with engineering andeconomics. Pharmacy practice is the discipline of pharmacywhich involves developing the professional roles of pharmacists. Disease-statemanagement, Clinical interventions (refusal to dispense a drug, recommendationto change and/or add a drug to a patient's pharmacotherapy, dosage adjustments,Professional development, Pharmaceutical care, Extemporaneous pharmaceuticalcompounding, Patient care, Drug abuse prevention, Prevention of druginteractions, including drug-drug interactions or drug-food interactions, Prevention (orminimization) of adverse events, Incompatibility, Drug discovery and evaluation, Community Pharmacy etc.,
· Drug discovery anddevelopment
· Clinical studies
· Supply chainmanagement
· Waste management
· Product management
Track 14: NMR and Analysis of Small Organic Molecules:
A compound is identified by matching its proton and/or carbonNMR spectra to NIH PubChem molecular structures. The matching process involvesanalyzing 1D proton, 1D carbon, DEPT, and/or HSQC spectra, and comparing thenumber of NMR resonances, detected proton and carbon shifts, likely number ofmethyl and methoxy groups, and an optionally specified molecular formula topredicted proton and carbon shifts of PubChem structures. A structureverification module rates the consistency between experimental spectralanalysis results and a proposed structure (not limited to PubChem structures)and assigns observed shifts to the proposed structure. The spectral analysis, structureidentification, and structureverification are largely automated ina software package and can be performed in minutes.
· Structure Identification
· Structure Verification
· Structure Elucidation
Track 15: Pharma Regulatory affairs:
As thepharmaceutical industries throughout the world are moving ahead towardsbecoming more and more competitive, regulatory agencies are being establishedin various countries across the globe. Regulatory agencies andorganizations play a vital role to meet the requirements of legal proceduresrelated to drug development process in a country. In the present scenario,pharmaceuticals are considered as the most highly regulated industries worldwide.The regulatory body ensures compliances in various legal and regulatory aspectsof a drug. Every country has its own regulatory authority, which is responsibleto enforce the rules and regulations and issue the guidelines to regulate drugdevelopment process, licensing, registration, manufacturing, marketing andlabeling of pharmaceutical products. World Health Organization(WHO), Pan American Health Organization (PAHO), World Trade Organization(WTO), International Conference on Harmonization (ICH), World IntellectualProperty Organization (WIPO) are some of the international regulatory agenciesand organizations which also playessential role in all aspects of pharmaceutical regulations related to drug product registration,manufacturing, distribution, price control, marketing, research and development,and intellectual property protection.
· HEALTH CANADA(CANADA)
· MCC(South Africa)
· ANVISA (Brazil)
· EMEA (European Union)
· SFDA (China)
· MoH (Sri Lanka)
Track 16: In-vitro Toxicity Testing in Drug Development:
Before submittingan IND application, the concerned drug must go through a comprehensive seriesof in-vitro and in-vivo toxicity testing toensure maximum safety in clinical trials.Considering the ethical issues and the cost of in-vivo animal tests, thepharmaceutical industry now relies more on in-vitro methods for toxicitytesting in the drug development phase. Screening for toxicity should startas early as possible to reveal inappropriate drugs early. This helps toeliminate such drugs from the drug development process timelyand saves resources. Hepatotoxicity (toxiceffects on the liver) and cardiotoxicity (toxic effects on the heart) are themost severe problems encountered in drug development and the major reason fordrug withdrawals. In addition, possible mutagenesis (genotoxicity) caused bythe concerned drug candidates is also observed frequently. Genotoxic compounds can cause mutations in DNA andpredispose to cancer and reproductive problems. Therefore, it’s crucial toscreen for genotoxicity. As per the regulatory guidelines, the standard testsfor genotoxicity screening include bacterial reverse mutation test (AMES) and amammalian genotoxicity assay.
· Ion channel assay
· hERG screening
· Cardiac action potentialassay
· In silico 3D-basedstructural model
· Functional assays:assessment of ATP, ADP, ATP/ADP ratios
· Cytology/Membraneleakage assays: LDH, AK test
· Mitochondrialassays: MTT, MTS, XTT
· Genomic/Proteomicassays: BrdU test
Track 17: Pharmaceutical Marketing:
Pharmaceutical marketing is the last element of an information continuum,where research concepts are transformed into practical therapeutic tools andwhere information is progressively layered and made more useful to the healthcare system. Thus, transfer of information to physicians through marketing is acrucial element of pharmaceutical innovation. By providing an informed choiceof carefully characterized agents, marketing assists physicians in matchingdrug therapy to individual patient needs. Pharmaceutical marketing is presentlythe most organized and comprehensive information system for updating physiciansabout the availability, safety, efficacy, hazards, and techniques of using medicines. The costs of pharmaceutical marketing aresubstantial, but they are typical of high-technology industries that mustcommunicate important and complex information to sophisticated users. Thesecosts are offset by savings resulting from proper use of medicines and fromlower drug costs owing to price competition.
Pharmaceutical company spending on marketing far exceeds that of itsresearch budget. In Canada, $1.7 billion was spent in 2004 to market drugs tophysicians; in the United States, $21 billion was spent in 2002. In 2005, moneyspent on pharmaceutical marketing in the United States was estimated at $29.9billion with one estimate as high as $57 billion. When the U.S. numbers arebroken down, 56% was free samples, 25% was pharmaceutical sales representative"detailing" (promoting drugs directly to) physicians, 12.5% wasdirect to user advertising, 4% on detailing to hospitals, and 2% on journalads.
Pharma Summit 2019 provides the best Place to share and gain knowledge. It is going to be a 2 - day event to ensure network for Drug Developing by using the analytical techniques and inventing formula, global knowledge on pharma, emerging technologies and can transform formulation and drug delivery, Innovative scientific techniques, new utilities of Pharmaceutical Sciences at one place.
Global Pharmaceutical Industry - Statistics & Facts:
The pharmaceutical industry is responsible for the development, production and of medications. Thus, its immense importance as a global sector is inarguable. In 2014, total had exceeded one trillion U.S. dollars for the first time. North America is responsible for the largest portion of these revenues, due to the leading role of the U.S. pharmaceutical industry. However, as in many other industries, the Chinese pharmaceutical sector has shown the highest over previous years. Still, the leading pharmaceutical companies come from the United States and Europe. Based on prescription sales, NYC-based is the world’s largest pharmaceutical company. In 2017, the company generated some 52.5 billion U.S. dollars in pure pharmaceutical sales. Other top global players from the United States include , Merck & Co., and AbbVie. Novartis and Roche from Switzerland, GlaxoSmithKline and AstraZeneca from the United Kingdom, and French are the European big five. Branded, patented medicines by far make up the largest . Humira, an anti-inflammatory drug, generated over 18.4 billion U.S. dollars of revenue worldwide in 2017. Oncologics continue to be the leading based on revenue. In 2017, cancer drugs made 81 billion U.S. dollars of revenue globally. Other major therapy classes were pain drugs and antidiabetics. More than any other industry, the pharmaceutical sector is highly dependent on its research and development segment. Some pharmaceutical companies invest 20 percent and more of their revenues in . The United States is a traditional stronghold of pharmaceutical innovation. The origin of most new substances introduced to the market can be traced back to the United States. Because of the steady loss of patent protection, the invention of new drugs is of vital importance for the pharmaceutical industry. Revenue losses due to patent expiry often are very significant, as can be seen with Pfizer’s from 2012 on.
Market Analysis in Spain:
Spending on medicines and healthcare in Spain witnessed steady growth in 2017, reflecting strong potential for new medicine development, infrastructure building and new entry/expansion opportunities. Both Pharmaceutical sales and consumption are on the rise and the outlook to 2025 remains robust driven by strong pharmaceutical market fundamentals. The goal of this report is to provide complete strategic analysis and forecast the pharmaceutical industry segments over the near to long term future. This report focuses its attention on pharmaceutical market in Spain and presents market trends, drivers and challenges facing the R&D professionals, investors, manufacturers, strategists, regulatory and other players. It also presents the pharmaceutical sales of prescription medicines and generic drugs. Further, pharmaceutical imports and exports data is also provided for the country. The research study on Spain healthcare spending provides outlook of total spending, government expenditure, private expenditure to 2025. Further, the level of out-of-pocket costs borne by patients is also analyzed. It additionally explores the level and growth of expenditure on healthcare, new drugs and ongoing research studies. The report also considers the Spain
healthcare industry prospects and infrastructure detailing hospitals, physicians, bed count, and other facilities. The report also analyzes the disease epidemiology trends through details of leading causes of death.
Recent Trends in Spain Pharmaceutical Market:
The pharmaceutical market in Spain is expected to rise in value from $23.7 billion in 2016 to $25.1 billion by 2021, research and consulting firm GlobalData noted in a report published in April 2017. The forecast represents a compound annual growth rate of close to 1%. Growth is being driven by consolidation of the biotechnology sector, government support, an infrastructure that encourages innovation, the availability of highly qualified workforce, and favourable cost benefit ratio of human capita, said the report. The aging population is also thought to have a key role in driving Spain’s healthcare sector to 2021. According to Global Data, the introduction of tax incentives for R&D spending by the Spanish government has eased the impact of austerity measures introduced in 2010, and the pharmaceutical industry has, as a result, made some recovery. Following the introduction of price containment measures by the Spanish government—which included forming homogenous groups of substitutable products so that pharmacists can provide the cheapest drug, eliminating the two-year period that existed for pharmaceutical companies to reduce the price of their medicines below the
reference price, and making it mandatory for pharmacists to dispense the cheapest available medicine—the pharmaceutical market contracted in value by 13.7% between 2010 and 2014. In 2015, the Spanish pharmaceutical industry invested $1.2 billion in R&D following the introduction of tax incentives, a move that has created a strong R&D base. The demand for innovative medicines is expected to help boost the local pharmaceutical market. The government is also investing in the implementation of electronic clinical records and the use of information and communication technology to integrate the services provided by public hospitals with those of the National Health System (Sistema Nacional de Salud, SNS). These efforts will be a boon to the industry. The introduction of e-health services allows patients to make appointments and obtain prescriptions online, improving access and thus driving the healthcare sector.
Pharmaceutical Companies in Spain:
· Merck & Co
· Johnson & Johnson
· Boehringer ingel
· Novo Nordisk
Major Pharma Associations around the Globe:
· International Pharmaceutical Federation (FIP)
· International Pharmaceutical Students' Federation (IPSF)
· European Association of Employed Community Pharmacists in Europe (EPhEU)
· Pharmaceutical Group of the European Union (PGEU)
· National Pharmacy Association
· Pharmaceutical Society of Northern Ireland
· Royal Pharmaceutical Society (RPS)
Biggest Pharmaceutical Companies in the World:
· Pfizer, The United States
· Novartis, Switzerland
· Merck & Co, The United States
· Sanofi S.A., France
· Roche-, Switzerland
· GlaxoSmithKline, The United Kingdom
· AstraZeneca, The United Kingdom
· Johnson & Johnson, The United States
· Eli Lilly & Co, The United States
· Abbott Laboratories, The United States
· Bristol-Myers Squibb, The United States
· Teva Pharmaceutical Industry, Israel
· Takeda pharma, Japan
· Bayer Schering, Germany
· Boehringer-Ingelheim, Germany
· Astellas, Japan
· Bristol-Myers Squibb, United Kingdom
· Novo Nordisk, Denmark
· Shire, Ireland
· Biogen, United Kingdom
· Daiichi-Sankyo, Japan
· Eisai, Japan
· Otsuka Pharmaceutical, Japan
· Gilead Sciences, The United States
· Mylan, The United States
Related Associations and Societies:
Societies in USA:
Drug Information Association | Canadian Society for Pharmaceutical Sciences (CSPS) | Chemical Society Reviews|American Association of Pharmaceutical Scientists (AAPS) | American Association of Pharmacy Technicians (AAPT) | American Associations of pharmaceutical scientists (AAPS) | The Pharmaceutical Research & Manufacturers Association (PhRMA)
Societies in Asia and Pacific:
Indonesian pharmaceutical association | Pharmaceutical Association of Malaysia (PhAMA) | Malaysian Pharmaceutical Society | International Society for Biological Therapy of Cancer
Societies in Europe:
Pharmaceutical Group of the European Union (PGEU) | The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS) | Association of the British Pharmaceutical Industry (ABPI) | Pharmaceutical Group of European Union (PGEU) | Pharmaceutical Group of European Union (PGEU)